Enhancement of posterolateral lumbar spine fusion using recombinant human bone morphogenetic protein-2 and mesenchymal stem cells delivered in fibrin glue

Abstract

Mesenchymal stem cells have shown great potential for accelerating bone healing. In the present study, we evaluate the efficacy of fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 composite for posterolateral spinal fusion in a rabbit model. Forty adult rabbits underwent posterolateral intertransverse fusion at the L5–L6 level. The animals were randomly divided into four groups based on the implant material: fibrin glue, fibrin glue/mesenchymal stem cells composite, fibrin glue-recombinant human bone morphogenetic protein-2 (fibrin glue/recombinant human bone morphogenetic protein-2) composite, and fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 composite. After six weeks, the rabbits were euthanized for manual palpation, radiographic examination, biomechanical testing, and histology. Manual palpation results showed that the fusion rate for fibrin glue, fibrin glue/mesenchymal stem cells, fibrin glue/recombinant human bone morphogenetic protein-2, and fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 was 0, 0, 40%, and 70%, respectively. Moreover, fusion rate determined by radiographic examination for fibrin glue, fibrin glue/mesenchymal stem cells, fibrin glue/recombinant human bone morphogenetic protein-2, and fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 was 0, 0, 40%, and 80%, respectively. Gray analysis showed that fibrin glue/recombinant human bone morphogenetic protein-2 group had higher ossification area and density than fibrin glue group; and fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 group had higher ossification area and density than fibrin glue/recombinant human bone morphogenetic protein-2 group. Formation of continuous bone masses between L5 and L6 level in mesenchymal stem cells/recombinant human bone morphogenetic protein-2/fibrin glue group was further confirmed by computed tomography scanning and three-dimensional reconstruction. Biomechanical testing demonstrated that the fusion strength (flexion, extension, lateral bending, and axial rotation) in fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 group is significantly higher than that in fibrin glue/recombinant human bone morphogenetic protein-2 group. The formation of mature bone tissues between transverse processes of the fused specimens from both fibrin glue/recombinant human bone morphogenetic protein-2, and fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 groups was confirmed by HE staining, and quantitative real-time polymerase chain reaction results showed the upregulation of CD31, type I collagen, osteocalcin, and osteonectin in the fibrin glue/mesenchymal stem cells/recombinant human bone morphogenetic protein-2 group. In conclusion, our findings show that mesenchymal stem cells delivered with recombinant human bone morphogenetic protein-2 using fibrin glue as carrier are more effective in enhancing spine fusion than recombinant human bone morphogenetic protein-2 without mesenchymal stem cells in the rabbit model.

Keywords

Mesenchymal stem cells recombinant human bone morphogenetic protein-2 fibrin glue spinal fusion fusion rate fusion strength

Get full access to this article

View all access options for this article.

References

Park

Hershman

Kim

. Updates in the use of bone grafts in the lumbar spine. Bull Hosp Jt Dis 2013; 71: 39–48.

Younger

Chapman

. Morbidity at bone graft donor sites. J Orthop Trauma 1989; 3: 192–195.

Banwart

Asher

Hassanein

. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. Spine 1995; 20: 1055–1060.

Galimberti

Lubelski

Healy

. A systematic review of lumbar fusion rates with and without the use of rhBMP-2. Spine 2015; 40: 1132–1139.

Kayanja

Orr

. Incidence and outcome of graft resorption in anterior lumbar interbody fusion: using femoral ring allografts and recombinant human bone morphogenetic protein-2. Spine 2014; 39: 374–380.

Luangphakdy

Shinohara

Pan

. Evaluation of rhBMP-2/collagen/TCP-HA bone graft with and without bone marrow cells in the canine femoral multi defect model. Eur Cells Mater 2015; 29: 57–68. discussion 68-59.

Ren

Yang

Dong

. Induction of reparative dentin formation in dogs with combined recombinant human bone morphogenetic protein 2 and fibrin sealant. Chin J Dent Res 1999; 2: 21–24.

Hattori

. Experimental investigations of osteogenesis and chondrogenesis by implant of BMP-fibrin glue mixture. Nihon Seikeigeka Gakkai zasshi 1990; 64: 824–834.

Lasa

Jr. Hollinger

Drohan

. Delivery of demineralized bone powder by fibrin sealant. Plastic Reconstr Surg 1995; 96: 1409–1417; discussion 1418.

10.

Geiger

Friess

. Collagen sponges for bone regeneration with rhBMP-2. Adv Drug Deliv Rev 2003; 55: 1613–1629.

11.

Pittenger

Mackay

Beck

. Multilineage potential of adult human mesenchymal stem cells. Science (New York, NY) 1999; 284: 143–147.

12.

Bruder

Jaiswal

Ricalton

. Mesenchymal stem cells in osteobiology and applied bone regeneration. Clin Orthop Relat Res 1998; 355 Suppl: S247–S256.

13.

Solchaga

Johnstone

Yoo

. High variability in rabbit bone marrow-derived mesenchymal cell preparations. Cell Transplant 1999; 8: 511–519.

14.

Kim

Choi

Yoon

. Evaluation of bone regeneration with biphasic calcium phosphate substitute implanted with bone morphogenetic protein 2 and mesenchymal stem cells in a rabbit calvarial defect model. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 2–9.

15.

Muller

Hildebrandt

Gerich

. BMP-2-transduced human bone marrow stem cells enhance neo-bone formation in a rat critical-sized femur defect. J Tissue Eng Regen Med 2015.

16.

Tan

She

Wang

. Repair of rat calvarial bone defects by controlled release of rhBMP-2 from an injectable bone regeneration composite. J Tissue Eng Regen Med 2012; 6: 614–621.

17.

Baiguera

Jungebluth

Mazzanti

. Mesenchymal stromal cells for tissue-engineered tissue and organ replacements. Transplant Int 2012; 25: 369–382.

18.

Huang

Zhang

. Systemic and local administration of allogeneic bone marrow derived mesenchymal stem cells promotes fracture healing in rats. Cell Transplant 2015; 24: 2642–2655.

19.

Paterson

Rash

Garvican

. Equine mesenchymal stromal cells and embryo-derived stem cells are immune privileged in vitro. Stem Cell Res Ther 2014; 5: 90–90.

20.

Xing

Han

. Differentiation of rabbit bone marrow mesenchymal stem cells into corneal epithelial cells in vivo and ex vivo. Mol Vis 2009; 15: 99–107.

21.

Abiraman

Varma

Umashankar

. Fibrin glue as an osteoinductive protein in a mouse model. Biomaterials 2002; 23: 3023–3031.

22.

Sandhu

Kanim

Kabo

. Effective doses of recombinant human bone morphogenetic protein-2 in experimental spinal fusion. Spine 1996; 21: 2115–2122.

23.

Singh

Smucker

Gill

. Use of recombinant human bone morphogenetic protein-2 as an adjunct in posterolateral lumbar spine fusion: a prospective CT-scan analysis at one and two years. J Spinal Disord Tech 2006; 19: 416–423.

24.

Yang

Fang

. Experimental research on spinal fusion with recombinant human bone morphogenetic protein-2 and bone marrow stromal cell composited tricalcium phosphate (TCP). Sheng wu yi xue gong cheng xue za zhi 2012; 29: 1156–1159, 1167.

25.

Konishi

Nakamura

Seki

. Hydroxyapatite granule graft combined with recombinant human bone morphogenic protein-2 for solid lumbar fusion. J Spinal Disord Tech 2002; 15: 237–244.

26.

Minamide

Kawakami

Hashizume

. Evaluation of carriers of bone morphogenetic protein for spinal fusion. Spine 2001; 26: 933–939.

27.

Namikawa

Terai

Suzuki

. Experimental spinal fusion with recombinant human bone morphogenetic protein-2 delivered by a synthetic polymer and beta-tricalcium phosphate in a rabbit model. Spine 2005; 30: 1717–1722.

28.

Chen

. Enhancement of posterolateral lumbar spine fusion using low-dose rhBMP-2 and cultured marrow stromal cells. J Orthop Research 2009; 27: 380–384.

29.

Arbes

Bosch

Lintner

. First clinical experience with heterologous cancellous bone grafting combined with the fibrin adhesive system (F.A.S.). Arch Orthop Trauma Surg 1981; 98: 183–188.

30.

Ono

Shikata

Shimizu

. Bone–fibrin mixture in spinal surgery. Clin Orthop Relat Res 1992; 275: 133–139.

31.

Dragoo

Samimi

Zhu

. Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. J Bone Jt Surg Br Vol 2003; 85: 740–747.

32.

Kim

Yang

Lee

. Effect of porcine bone morphogenetic protein on healing of bone defect in the rabbit radius. Yonsei Med J 1992; 33: 54–63.

33.

Nakamura

. Experimental study on repair of the defect of the pars interarticularis in rat with bone morphogenetic protein and fibrin glue. Nihon Seikeigeka Gakkai zasshi 1992; 66: 753–762.

34.

Chang

Wong

. Mesenchymal stem cells expressing baculovirus-engineered BMP-2 and VEGF enhance posterolateral spine fusion in a rabbit model. Spine J 2015; 15: 2036–2044.

35.

Karageorgiou

Kaplan

. Porosity of 3D biomaterial scaffolds and osteogenesis. Biomaterials 2005; 26: 5474–5491.

36.

Rowe

Stegemann

. Interpenetrating collagen-fibrin composite matrices with varying protein contents and ratios. Biomacromolecules 2006; 7: 2942–2948.

37.

Erkan

Cakmak

Kocer

. Effects of fibrin glue on nasal septal tissues. Laryngoscope 2007; 117: 491–496.

38.

Gosk

Knakiewicz

Wiacek

. The use of the fibrin glue in the peripheral nerves reconstructions. Polimery w medycynie 2006; 36: 11–15.

39.

Fang

Peng

Chen

. Biocompatibility studies on fibrin glue cultured with bone marrow mesenchymal stem cells in vitro. J Huazhong Univ Sci Technolog Med Sci 2004; 24: 272–274.

40.

Minamide

Yoshida

Kawakami

. The use of cultured bone marrow cells in type I collagen gel and porous hydroxyapatite for posterolateral lumbar spine fusion. Spine 2005; 30: 1134–1138.

41.

Bartholomew

Sturgeon

Siatskas

. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002; 30: 42–48.

42.

Di Nicola

Carlo-Stella

Magni

. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838–3843.